Journal article
STEM-17. THE UROKINASE RECEPTOR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN BRAIN CANCERS
Abstract
Abstract Glioblastoma (GBM) is the common malignant brain tumor in adults, accounting for approximately 15% of all CNS tumors, and 48.6% of malignant brain tumors, with a median survival of approximately 15 months. GBM is characterized by extensive inter- and intra-tumoral heterogeneity and an extremely immunosuppressive tumor microenvironment. Following Standard-of-Care surgical resection and chemoradiotherapy, patients inevitably relapse, at …
Authors
Maich W; Shaikh MV; Puri A; Mobilio D; Ananda A; Venugopal C; Rossotti M; Mikolajewicz N; Chokshi C; Salim S
Journal
Neuro-Oncology, Vol. 26, No. Supplement_8, pp. viii61–viii62
Publisher
Oxford University Press (OUP)
Publication Date
November 11, 2024
DOI
10.1093/neuonc/noae165.0243
ISSN
1522-8517